Item 7.01 Regulation FD Disclosure.

On January 5, 2023, SAB Biotherapeutics, Inc. (the "Company" or "SAB") issued a press release announcing new findings from a collaboration with a global biotechnology firm, CSL, confirming SAB's DiversitAb™ platform can generate functional fully-human anti-idiotype polyclonal antibodies that can effectively target and neutralize auto-antibodies associated with autoimmune diseases.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

The information furnished under this Item 7.01, including Exhibit 99.1, will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



Exhibit Number   Description
99.1               Press Release of the Company, dated January 5, 2023
104              Cover Page Interactive Data File-the cover page XBRL tags are
                 embedded within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses